MIT family translocation renal cell carcinoma
MONDO:0017886MiT family translocation renal cell carcinoma (t-RCC) is a rare subtype of renal cell carcinoma with recurrent genetic abnormalities, harboring rearrangements of the TFE3 (Xp11 t-RCC) or TFEB [t(6;11) t-RCC] genes. The t(6;11) t-RCC has distinctive histologic features of biphasic appearance with larger epitheloid and smaller eosinophilic cells. The symptoms are usually non-specific and include hematuria, flank pain, palpable abdominal mass and/or systemic symptoms of anemia, fatigue and fever.
Also known as: carcinoma associated with MITF/TFE translocation, translocation renal cell carcinoma
2782 clinical trials for this condition and its sub-types, 6 tagged with MIT family translocation renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of MIT family translocation renal cell carcinoma
-
TFEB-rearranged renal cell carcinoma 0 trials
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Phase 2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Supercharged immune cells take on advanced kidney and bladder tumors
Disease control OngoingThis early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…
Early phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC